Is ENSG a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for The Ensign Group runs a network of independently operated skilled nursing facilities (ENSG) rests on Serial-acquisition growth engine: Ensign's core strategy is buying underperforming skilled nursing and senior living facilities and improving their operations. Revenue (TTM) is ~$5.3B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Ensign derives the majority of its revenue from Medicare and Medicaid, so any cut, freeze, or unfavorable change to government reimbursement rates would pressure margins directly. Whether ENSG is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
The Ensign Group runs a network of independently operated skilled nursing facilities, senior living communities, and rehabilitation services across the United States, plus a growing real estate arm (Standard Bearer). As of mid-2026 its subsidiaries operated roughly 398 healthcare operations, including about 48 senior living communities, across 17 states, with a real estate portfolio of roughly 183 properties. The business model is to acquire underperforming but strategically located facilities and turn them into profitable local operations, generating revenue mostly from Medicare, Medicaid, and private-insurance reimbursement for short-term rehab and long-term care. The investment picture centers on durable, acquisition-fueled growth. Ensign has delivered years of double-digit revenue and earnings gains by improving occupancy, skilled mix, and staff retention at newly acquired sites while keeping a strong balance sheet. In Q1 2026 revenue rose about 18% to roughly $1.39 billion and adjusted EPS grew more than 20%, prompting management to raise full-year guidance. The trade-off is a premium valuation and heavy dependence on government reimbursement rates and labor costs, which makes execution and policy the key variables rather than demand, since an aging population supplies a long structural tailwind.
What's the case for buying ENSG?
1. Serial-acquisition growth engine
Ensign's core strategy is buying underperforming skilled nursing and senior living facilities and improving their operations. In 2026 it kept adding operations (including a multi-facility Texas expansion for roughly $342 million) from what management calls a robust, seller-friendly pipeline. This repeatable playbook is the main driver of its long record of double-digit revenue growth.
2. Occupancy and skilled-mix gains
Same-facility and transitioning occupancy reached record levels near 84 to 85 percent in early 2026, while a richer skilled mix (more Medicare and managed-care days) lifted margins. Improving director-of-nursing retention and lower staff turnover reduced reliance on expensive agency labor, directly supporting profitability.
3. Real estate value via Standard Bearer
Ensign owns a large and growing portfolio of the underlying real estate through its captive REIT subsidiary, giving it control over roughly 183 properties. Owning the buildings adds a rental income stream, provides financing flexibility for deals, and represents embedded asset value beyond the operating business.
4. Aging-population demand tailwind
Long-term demographics favor post-acute care as the US population ages and demand for skilled nursing and senior living rises. This structural tailwind supports occupancy and gives Ensign a long runway of facilities to acquire and turn around across its 17-state footprint.
What are the risks to ENSG?
Ensign derives the majority of its revenue from Medicare and Medicaid, so any cut, freeze, or unfavorable change to government reimbursement rates would pressure margins directly. The skilled nursing industry is labor-intensive and exposed to persistent workforce shortages and wage inflation, and proposed federal minimum-staffing mandates could raise costs if reinstated. Growth depends on continuously finding and integrating acquisitions at attractive prices, so a slower pipeline or integration missteps would slow the compounding. The stock also trades at a premium valuation, which leaves less cushion if growth decelerates. Finally, the sector carries regulatory, litigation, and quality-of-care compliance risk that can produce fines or reputational damage.
How is ENSG valued? (as of July 2026)
Snapshot for ENSG as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$5.3B
- 2026 revenue guidance: ~$5.81B to $5.86B
- 2026 EPS guidance (diluted): ~$7.48 to $7.62
- Market cap: ~$9.9B
- Trailing P/E: ~27x
- Forward P/E: ~20x
Ensign trades at a premium to typical healthcare-facility peers, reflecting its consistent double-digit growth and strong balance sheet (roughly $540 million cash against about $143 million of debt in early 2026). Q1 2026 revenue grew about 18% year over year to roughly $1.39 billion with adjusted EPS up more than 20%, and management raised full-year guidance. The premium multiple assumes the acquisition-led growth continues.
How do you decide if ENSG is a buy?
Rather than asking whether ENSG is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ENSG indirectly through an index or sector ETF before adding more.
For the full picture, see the ENSG stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ENSG against your real portfolio and see your actual exposure before deciding.
The bottom line on ENSG
The bottom line: The Ensign Group runs a network of independently operated skilled nursing facilities's story right now is Serial-acquisition growth engine, with revenue (ttm) at ~$5.3B. If you believe that narrative continues, the call is about sizing ENSG sensibly and checking overlap with what you own; if you doubt it (the risk: ensign derives the majority of its revenue from Medicare and Medicaid, so any cut, freeze, or unfavorable change to government reimbursement rates would pressure margins directly.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around ENSG with Walnut
Use The Ensign Group runs a network of independently operated skilled nursing facilities as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ENSG a good stock to buy right now?
+
The case for The Ensign Group runs a network of independently operated skilled nursing facilities right now is Serial-acquisition growth engine, with revenue (ttm) at ~$5.3B. If you believe that thesis holds, ENSG is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is ensign derives the majority of its revenue from Medicare and Medicaid, so any cut, freeze, or unfavorable change to government reimbursement rates would pressure margins directly. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does The Ensign Group runs a network of independently operated skilled nursing facilities do?
+
The Ensign Group runs a network of independently operated skilled nursing facilities, senior living communities, and rehabilitation services across the United States, plus a growin
What are the main risks of ENSG?
+
Ensign derives the majority of its revenue from Medicare and Medicaid, so any cut, freeze, or unfavorable change to government reimbursement rates would pressure margins directly. The skilled nursing industry is labor-intensive and exposed to persistent workforce shortages and wage inflation, and proposed federal minimum-staffing mandates could raise costs if reinstated. Growth depends on continuously finding and integrating acquisitions at attractive prices, so a slower pipeline or integration missteps would slow the compounding. The stock also trades at a premium valuation, which leaves less cushion if growth decelerates. Finally, the sector carries regulatory, litigation, and quality-of-care compliance risk that can produce fines or reputational damage.
What does The Ensign Group do?
+
Ensign operates skilled nursing facilities, senior living communities, and rehabilitation and therapy services across the US through a network of independently run local subsidiaries. It also owns much of the underlying real estate through its Standard Bearer arm.
How does Ensign make money?
+
It earns revenue mostly from Medicare, Medicaid, and private insurance reimbursement for short-term rehabilitation and long-term care at its skilled nursing and senior living facilities, plus rental income from the properties it owns.
Is ENSG a growth stock?
+
Ensign has delivered years of double-digit revenue and earnings growth driven by acquisitions and operational improvements, so it is generally viewed as a growth-oriented compounder rather than a slow, mature healthcare stock.
What were Ensign's recent results?
+
In Q1 2026, revenue rose about 18% year over year to roughly $1.39 billion, GAAP EPS was $1.67 and adjusted EPS $1.85, and management raised full-year 2026 guidance to roughly $5.81 to $5.86 billion in revenue and about $7.48 to $7.62 in diluted EPS.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ENSG; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.